Trial Profile
A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2021
Price :
$35
*
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms MINDSET
- Sponsors Axovant Gene Therapies; Axovant Sciences; Sio Gene Therapies [CEASED]
- 08 Jan 2018 According to a company media release, Axovant Sciences has decided to discontinue intepirdine program based on negative results from MINDSET, HEADWAY and Gait and Balance studies.
- 26 Sep 2017 Primary endpoint has not been met. (Change from baseline on Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale)
- 26 Sep 2017 Primary endpoint has not been met. (Change from baseline on Alzheimers Disease Assessment Scale - Cognitive Subscale 11 items (ADAS-Cog-11))